Drug intelligence / Profile preview

Diabin

Development stage: Preclinical
Lead developer: SB Pharma
Administration: Oral

Overview

**Diabin** is an Ayurvedic herbal medicine product from SB Pharma, marketed for support of blood-glucose regulation in people with diabetes-related symptoms. SB Pharma describes it as a selected-herb formulation intended to promote normal glucose metabolism and reduce blood-sugar fluctuations, thirst, frequent urination, and fatigue; however, the specific botanical ingredients, molecular targets, dosage form, and evidence supporting a defined pharmacologic mechanism are not disclosed on the public product page. ([sbpharma.com](https://sbpharma.com/product/diabin/))

Brand names: Diabin

Beyond the preview

Go deeper on Diabin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Diabin.

Explore the full profile